THORN RUN PARTNERS for BIOGEN
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 20, 2020 | $40,000 | Replaced |
| 1st Quarter - Amendment | Apr 20, 2020 | $50,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Biosimilar policies legislation. Legislation regarding drug importation. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BEAU SCHUYLER | Legislative Director - Cong. Tanner, Legislative Director - Cong. McIntyre |
Medicare/Medicaid MMM
Legislation that would alter payment policies under Medicare Part B for drugs and biologics. Issues pertaining to Medicare Part D. International Pricing Indexing proposals.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BEAU SCHUYLER | Legislative Director - Cong. Tanner, Legislative Director - Cong. McIntyre |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.